LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

LLY

1,073.71

-0.24%↓

JNJ

207.38

-0.2%↓

ABBV

230

-0.06%↓

UNH

329.54

+0.55%↑

AZN

92.78

+0.3%↑

Search

Celldex Therapeutics Inc

Deschisă

SectorSănătate

26.13 -2.35

Rezumat

Modificarea prețului

24h

Curent

Minim

25.18

Maxim

26.51

Indicatori cheie

By Trading Economics

Venit

-10M

-67M

EPS

-1.01

Marjă de profit

-7,753.425

Angajați

186

EBITDA

-9.8M

-73M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+104.99% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

307M

1.8B

Deschiderea anterioară

28.48

Închiderea anterioară

26.13

Sentimentul știrilor

By Acuity

50%

50%

152 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Celldex Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 dec. 2025, 21:41 UTC

Achiziții, Fuziuni, Preluări

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 dec. 2025, 14:57 UTC

Achiziții, Fuziuni, Preluări

Accenture to Acquire Cabel Industry from Fibonacci Group

25 dec. 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dec. 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dec. 2025, 00:20 UTC

Achiziții, Fuziuni, Preluări

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dec. 2025, 22:22 UTC

Achiziții, Fuziuni, Preluări

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec. 2025, 21:26 UTC

Achiziții, Fuziuni, Preluări

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec. 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 dec. 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec. 2025, 19:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

24 dec. 2025, 19:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec. 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 dec. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 dec. 2025, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

24 dec. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 dec. 2025, 17:08 UTC

Achiziții, Fuziuni, Preluări

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec. 2025, 16:53 UTC

Achiziții, Fuziuni, Preluări

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 dec. 2025, 16:31 UTC

Market Talk
Achiziții, Fuziuni, Preluări

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 dec. 2025, 16:28 UTC

Achiziții, Fuziuni, Preluări

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 dec. 2025, 16:17 UTC

Market Talk

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 dec. 2025, 15:33 UTC

Achiziții, Fuziuni, Preluări

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 dec. 2025, 15:30 UTC

Achiziții, Fuziuni, Preluări

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec. 2025, 15:19 UTC

Achiziții, Fuziuni, Preluări

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec. 2025, 14:49 UTC

Achiziții, Fuziuni, Preluări

Mexico's Ollamani Sells Stake in Azteca Stadium

24 dec. 2025, 14:19 UTC

Market Talk

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 dec. 2025, 14:08 UTC

Achiziții, Fuziuni, Preluări

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec. 2025, 14:06 UTC

Market Talk

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 dec. 2025, 13:24 UTC

Market Talk

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 dec. 2025, 12:59 UTC

Achiziții, Fuziuni, Preluări

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec. 2025, 12:51 UTC

Achiziții, Fuziuni, Preluări

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Comparație

Modificare preț

Celldex Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

104.99% sus

Prognoză pe 12 luni

Medie 55 USD  104.99%

Maxim 90 USD

Minim 24 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCelldex Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

9

Cumpărare

0

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

18.91 / 20.63Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

152 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat